Inhibitors of expression and / or function
IL330165A0Pending Publication Date: 2026-08-01E THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- IL330165
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-13
- Filing Date
- 2024-12-20
- Publication Date
- 2026-08-01
AI Technical Summary
Technical Problem
Current treatments for metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and obesity lack effective inhibitors that specifically target the SLC25A5/ANT2 gene, which is involved in mitochondrial function and adipogenesis.
Method used
Development of inhibitors, such as siRNA oligomers, that specifically target the expression and function of the SLC25A5/ANT2 gene, which can be used alone or in combination with other therapeutic agents like GLP-1 agonists and FGF-21 analogues, to treat metabolic diseases.
Benefits of technology
The use of these inhibitors effectively reduces adipogenesis and improves metabolic parameters, such as liver steatosis and inflammation, demonstrating potential in treating NAFLD and obesity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a metabolic disease or disorder, such as a metabolic disease or disorder associated with non-alcoholic fatty liver disease (NAFLD) and / or obesity and / or a disease or disorder associated with adipogenesis.
Need to check novelty before this filing date? Find Prior Art